financetom
Business
financetom
/
Business
/
Check Point Q3 Earnings: Security Subscriptions Revenue Soars 11.5%, But Margins Slip As Expenses Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Check Point Q3 Earnings: Security Subscriptions Revenue Soars 11.5%, But Margins Slip As Expenses Rise
Nov 3, 2024 1:46 PM

Check Point Software Technologies Ltd ( CHKP )  reported fiscal third-quarter revenue growth of 7% year-on-year to $635.10 million, marginally missing the analyst consensus estimate of $635.14 million. 

The American-Israeli enterprise security solution provider’s adjusted EPS of $2.25 was in line with the analyst consensus estimate.

Revenue from Products and licenses grew by 4.1% to $118.9 million, Security subscriptions increased 11.5% year over year to $276.9 million, and Software updates and maintenance rose 2.4% year over year to $239.3 million.

Also Read: Apple Unveils New iMac: M4 Chip Brings Faster Speeds and Smarter AI Features

Margin: Adjusted operating margin declined to 43% from 45% the prior year. The operating margin declined to 34% from 38% a year ago as operating expenses surged by 12.5% Y/Y.

The company generated $248.9 million in operating cash flow, compared to $222.3 million a year ago, and held $2.87 billion in cash and equivalents as of September-end.

“Check Point delivered great third quarter financial results that were bolstered by double-digit Infinity Platform growth. This success is underscored by double-digit revenue growth in Harmony Email and Infinity Global Services,” said Gil Shwed, Check Point founder and CEO. “We expanded our offerings into the Security Operation Center (SOC) market with the Cyberint acquisition that delivers proactive, AI powered threat intelligence and exposure management.”

Check Point Software Technologies ( CHKP ) stock gained 37% year-to-date.

Price Action: CHKP shares traded lower by 7.69% at $191.96 premarket at the last check Tuesday.

Also Read:

Alibaba Becomes Key Holding in Chinese Fund Manager’s Portfolio, Economic Measures Spark Interest in Leading Tech

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blackstone Life Sciences to Co-Fund Leukemia Drug Trials
Blackstone Life Sciences to Co-Fund Leukemia Drug Trials
Mar 11, 2026
07:41 AM EST, 02/23/2026 (MT Newswires) -- Blackstone Life Sciences (BX) said Monday it established a research financing agreement to advance the clinical development of bleximenib, an investigational drug to treat acute myeloid leukemia. Blackstone and Johnson & Johnson ( JNJ ) will jointly finance a portion of current and upcoming trials evaluating bleximenib, the company said. Bleximenib is an...
InMode to Discontinue Potential Transaction Process
InMode to Discontinue Potential Transaction Process
Mar 11, 2026
07:39 AM EST, 02/23/2026 (MT Newswires) -- InMode ( INMD ) said Monday it will discontinue the process of a potential transaction following a review of proposals by the company's independent transaction committee. The committee concluded that none of the final proposals were adequate or in the best interests of the company and its shareholders, InMode ( INMD ) said....
BRIEF-Stanley Martin Homes To Acquire United Homes Group
BRIEF-Stanley Martin Homes To Acquire United Homes Group
Mar 11, 2026
Feb 23 (Reuters) - United Homes Group ( UHG ) ​Inc: * STANLEY ‌MARTIN HOMES ⁠TO ACQUIRE UNITED ⁠HOMES ‌GROUP * ‌UNITED HOMES GROUP ​INC - ‌ALL-CASH DEAL VALUES UNITED ​HOMES AT $221 ​MILLION * ‌UNITED HOMES GROUP INC - CO'S ⁠SHAREHOLDERS TO ⁠RECEIVE $1.18 PER SHARE IN CASH UNDER ⁠DEAL * ‌UNITED ‌HOMES GROUP ⁠INC - UPON COMPLETION OF...
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment
Mar 11, 2026
07:41 AM EST, 02/23/2026 (MT Newswires) -- Armata Pharmaceuticals ( ARMP ) said Monday the US Food and Drug Administration has granted its experimental AP-SA02 candidate for intravenous use as a qualified infectious disease product for adjunct treatment of complicated bacteremia. The designation covers bacteremia caused by methicillin-sensitive Staphylococcus aureus or methicillin resistant S. aureus. The designation makes the product...
Copyright 2023-2026 - www.financetom.com All Rights Reserved